Wolfes, J.; Ellermann, C.; Broer, N.; Rath, B.; Willy, K.; Leitz, P.R.; Lange, P.S.; Eckardt, L.; Frommeyer, G.
Antiarrhythmic Effect of Ranolazine in Combination with Selective NCX-Inhibition in an Experimental Model of Atrial Fibrillation. Pharmaceuticals 2020, 13, 321.
https://doi.org/10.3390/ph13100321
AMA Style
Wolfes J, Ellermann C, Broer N, Rath B, Willy K, Leitz PR, Lange PS, Eckardt L, Frommeyer G.
Antiarrhythmic Effect of Ranolazine in Combination with Selective NCX-Inhibition in an Experimental Model of Atrial Fibrillation. Pharmaceuticals. 2020; 13(10):321.
https://doi.org/10.3390/ph13100321
Chicago/Turabian Style
Wolfes, Julian, Christian Ellermann, Niklas Broer, Benjamin Rath, Kevin Willy, Patrick Robert Leitz, Philipp Sebastian Lange, Lars Eckardt, and Gerrit Frommeyer.
2020. "Antiarrhythmic Effect of Ranolazine in Combination with Selective NCX-Inhibition in an Experimental Model of Atrial Fibrillation" Pharmaceuticals 13, no. 10: 321.
https://doi.org/10.3390/ph13100321
APA Style
Wolfes, J., Ellermann, C., Broer, N., Rath, B., Willy, K., Leitz, P. R., Lange, P. S., Eckardt, L., & Frommeyer, G.
(2020). Antiarrhythmic Effect of Ranolazine in Combination with Selective NCX-Inhibition in an Experimental Model of Atrial Fibrillation. Pharmaceuticals, 13(10), 321.
https://doi.org/10.3390/ph13100321